Susceptibility of half knockout strains to CYP51 inhibitors (EC50, μM): compounds with decreased activity on HKO + CYP strains. by Laura-Isobel McCall (222498)

Decreased peritumoral myofibroblasts in the MC38 S.C. tumors of <i>S100a4-Cre; Ext1</i>^<i>f/f</i> mice. by Ayumi Niwa (6256790)

KDM6A mRNA expression is decreased in PTFE mice. by Simon Lebek (9756148)

Body weight, femoral length and <i>Notch3</i> transcripts of 8.5–9 week old male <i>Notch3</i>^{<i>em1Ecan</i>} mutant mice (gray bars) and littermate controls (white bars)... by Ernesto Canalis (516050)

Acute exercise decreased plasma insulin and glucose. by Mirian A. Kurauti (3146271)

Signal random fluctuations. by Olga N. Milekhina (812701)

Density plots of normalised consumer final power (PC) for the six example networks, shown over decreasing ratios of mean consumer to mean resource potential, . by Natalie Davis (8556036)

“…<p>Each plot shows the density for the normalised consumer final power at = 0.75, 0.5, and 0.25, from left to right, as the ratio decreases due to increased resource flow during the simulation. …”

Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab) by William Owens (20777)

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Five compounds significantly decrease MAPK1 phosphorylation in K562 cells. by Pamela Y. Ting (713174)

Effect of specific inhibitors on CYP-mediated CK (50 μM) metabolism in HLMs. by Jian Xiao (253329)

Molecular mass of peak samples of HWHF by LC-MS analysis. by Prawej Ansari (12191266)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: